scholarly journals Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis

Drugs in R&D ◽  
2017 ◽  
Vol 17 (4) ◽  
pp. 597-605
Author(s):  
Richa Pandey ◽  
Julia B. Zella ◽  
Jinge G. Zhu ◽  
Lori A. Plum ◽  
Margaret Clagett-Dame ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Secondary Hyperparathyroidism ◽  
Vitamin D Receptor ◽  
Oral Vitamin ◽  
Dihydroxyvitamin D3 ◽  
Receptor Activator

Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease

2014 ◽  
Vol 19 (3) ◽  
pp. 371-378 ◽  
Author(s):  
Shinichi Sueta ◽  
◽  
Kunio Morozumi ◽  
Asami Takeda ◽  
Keiji Horike ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Receptor ◽  
Pulmonary Congestion ◽  
Advanced Chronic Kidney Disease ◽  
Receptor Activator

scholarly journals Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol

2015 ◽  
Vol 31 (7) ◽  
pp. 1081-1087 ◽  
Author(s):  
Charlotte A. Keyzer ◽  
Maarten A. de Jong ◽  
G. Fenna van Breda ◽  
Marc G. Vervloet ◽  
Gozewijn D. Laverman ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Receptor ◽  
Study Protocol ◽  
Urinary Albumin Excretion ◽  
Urinary Albumin ◽  
Dietary Sodium ◽  
Sodium Restriction ◽  
Receptor Activator

scholarly journals Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease

2018 ◽  
Vol 21 (2) ◽  
pp. 128-134
Author(s):  
Lilit V. Egshatyan ◽  
Natalya G. Mokrisheva
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Secondary Hyperparathyroidism ◽  
Vitamin D Receptor ◽  
Receptor Activation ◽  
Mineral Density

Secondary hyperparathyroidism is an early complication of chronic kidney disease, with increasing severity as the glomerular filtration rate decreases and characterized by a progressive increase in parathyroid hormone and growth of the parathyroid glands. It is generally accepted that a deficiency in active form of vitamin D or calcitriol levels seems to play a relevant role in its development and progression of secondary hyperparathyroidism. A reduction in plasma calcitriol levels occurs early in renal disease. Major renal guidelines recommend use of vitamin D for secondary hyperparathyroidism in chronic kidney disease. In the treatment vitamin D receptor activation inhibit glandular hyperplasia; reduce parathyroid hormone levels impact on bone turnover and mineral density. Treatment with calcitriol can occasionally result in hypercalcemia and hyperphosphatemia in renal patients due promotes intestinal calcium and phosphorus absorption. This limits its suitability for the treatment. But next generation vitamin-D analogs such as paricalcitol have lower intestinal absorption of calcium, phosphorous and significantly lowers renin levels, albuminuria and blood pressure. In this article, we present the case of a Caucasian male with type 2 diabetes and secondary hyperparathyroidism in stages 34 chronic kidney disease. Our case study shows that in treating for secondary hyperparathyroidisms selective vitamin D receptor activation with paricalcitol reduction of levels parathyroid hormone, albuminuria, offering low chance hypercalcemia, hyperphosphatemia and other side effects.

scholarly journals Study of The Polymorphism BsmI and TaqI in Vitamin D Receptor Gene in Egyptian Patients With Chronic Kidney Disease

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
F M K Mohamed ◽  
M M Osman ◽  
I G Nessim ◽  
A I Abdelmageed ◽  
H A Abdelsattar ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Gene Polymorphism ◽  
Secondary Hyperparathyroidism ◽  
Vitamin D Deficiency ◽  
Vitamin D Receptor ◽  
Receptor Gene ◽  
Vitamin D Receptor Gene ◽  
Egyptian Patients

Abstract Background Chronic kidney disease (CKD) is a major public health problem and a leading cause of morbidity and mortality worldwide. Chronic kidney disease mineral and bone disorders (CKD-MBD) is a common complication of CKD and an important cause of morbidity and decreased quality of life. Serum levels of 25-hydroxy vitamin D and parathyroid hormone (PTH) provide an accurate picture of bone turnover and mineralization states therefore they could be used with other serum bone biomarkers as non-invasive sensitive bone markers to help management of MBD in CKD. Due to the complex role played by vitamin D in kidney disease, the genotyping for vitamin D receptor (VDR) variants in CKD patients has been regarded as a way for improving the management of the disease. Objective The aim of the present work was to study the association of vitamin D receptor gene polymorphisms BsmI and TaqI with the chronic kidney disease and to assess its relationship with development and progression of chronic kidney disease-mineral bone disease. Subjects and Methods The study was conducted on 60 CKD-MBD patients in addition to 30 age- and sex- matched subjects serving as a healthy control group. Patients were subdivided into two subgroups according to the stage of CKD: subgroup 1a; 30 patients with CKD-MBD under conservative management (stages: 3 and 4 CKD) and subgroup 1b; 30 CKD-MBD patients with end-stage CKD on regular hemodialysis. Determination of BsmI (rs1544410, A>G) and TaqI (rs731236, C>T) polymorphisms of VDR gene was carried out using restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR). Results The result of the present study revealed that VDR BsmI (rs1544410) gene polymorphism and alleles (Bb, bb) were not associated with susceptibility to the CKD or development and progression of CKD-MBD in the studied CKD-MBD patients. However, having the gene variants of VDR TaqI (rs731236) tt homotypic genotype increased the susceptibility to CKD-MBD compared to having the gene variant TT wild genotype and Tt heterotypic genotype. Moreover, VDR polymorphisms were associated with the mineral status in CKD-MBD Egyptian patients. The VDR BsmI wild (BB) genotypes and the VDR TaqI homotypic (tt) variant were found to be associated with development of severe secondary hyperparathyroidism, hypocalcemia and vitamin D deficiency in the studied Egyptian patients with CKD-MBD. Conclusion VDR BsmI gene polymorphism failed to prove any association with susceptibility to the CKD or development and progression of CKD-MBD. However, VDR TaqI tt homotypic genotype increased the susceptibility to CKD-MBD and progression toward severe secondary hyperparathyroidism, hypocalcemia and vitamin D deficiency.

scholarly journals Selective Vitamin D Receptor Activation as Anti-Inflammatory Target in Chronic Kidney Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
J. Donate-Correa ◽  
V. Domínguez-Pimentel ◽  
M. L. Méndez-Pérez ◽  
M. Muros-de-Fuentes ◽  
C. Mora-Fernández ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Secondary Hyperparathyroidism ◽  
Vitamin D Receptor ◽  
Mononuclear Cells ◽  
Receptor Activation ◽  
Control Group ◽  
Pth Level

Paricalcitol, a selective vitamin D receptor (VDR) activator used for treatment of secondary hyperparathyroidism in chronic kidney disease (CKD), has been associated with survival advantages, suggesting that this drug, beyond its ability to suppress parathyroid hormone, may have additional beneficial actions. In this prospective, nonrandomised, open-label, proof-of-concept study, we evaluated the hypothesis that selective vitamin D receptor activation with paricalcitol is an effective target to modulate inflammation in CKD patients. Eight patients with an estimated glomerular filtration rate between 15 and 44 mL/min/1.73 m2and an intact parathyroid hormone (PTH) level higher than 110 pg/mL received oral paricalcitol (1 μg/48 hours) as therapy for secondary hyperparathyroidism. Nine patients matched by age, sex, and stage of CKD, but a PTH level <110 pg/mL, were enrolled as a control group. Our results show that five months of paricalcitol administration were associated with a reduction in serum concentrations of hs-CRP (13.9%,P<0.01), TNF-α(11.9%,P=0.01), and IL-6 (7%,P<0.05), with a nonsignificant increase of IL-10 by 16%. In addition, mRNA expression levels of the TNFαand IL-6 genes in peripheral blood mononuclear cells decreased significantly by 30.8% (P=0.01) and 35.4% (P=0.01), respectively. In conclusion, selective VDR activation is an effective target to modulate inflammation in CKD.

Sign in / Sign up

Export Citation Format

Share Document